---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000096"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:32:29.246057+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Johns Hopkins Hospital treats first commercial TULSA-PRO case, expanding access to advanced prostate care

## Summary
- Johns Hopkins Hospital treated its first non-clinical-trial prostate cancer patient using Profound's TULSA-PRO system.
- Milestone coincides with the opening of Johns Hopkins Medicine's new interventional MRI suite.
- TULSA-PRO delivers robotically controlled directional ultrasound under real-time MRI thermography to ablate prostate tissue.
- Johns Hopkins was an early participant in the TACT and CAPTAIN trials that supported FDA clearance of TULSA-PRO.

## SEC filing metadata
- accession: 0001171843-26-000096
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184326000096/0001171843-26-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184326000096/f8k_010626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000096
- JSON: https://secwatch.observer/filing/0001171843-26-000096.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.